Expression of extracellular matrix proteins: tenascin-C, fibronectin and galectin-3 in prostatic adenocarcinoma

  • Monika Ulamec Ljudevit Jurak Department of Pathology, Sestre milosrdnice University Hospital Center” and Department of Pathology, School of Medicine, University of Zagreb, Zagreb, Croatia
  • Davor Tomas Ljudevit Jurak Department of Pathology, Sestre milosrdnice University Hospital Center” and Department of Pathology, School of Medicine, University of Zagreb, Zagreb, Croatia
  • Tihana Dzombeta Department of Pathology, School of Medicine, University of Zagreb, Zagreb, Croatia
  • Igor Tomaskovic Department of Urology, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
  • Borislav Spajić Department of Urology, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
  • Božo Krušlin Ljudevit Jurak Department of Pathology, Sestre milosrdnice University Hospital Center” and Department of Pathology, School of Medicine, University of Zagreb, Zagreb, Croatia

Abstract

Introduction: The interchanged stromal-epithelial relations and altered expression profiles of various extracellular matrix (ECM) proteins creates a suitable microenvironment for cancer development and growth. We support the opinion that remodeling of the extracellular matrix (ECM) plays an important role in the cancer progression. The aim of this study was to examine the expression of ECM proteins tenascin-C, fibronectin and galectin-3 in prostatic adenocarcinoma.
Methods: Glands and surrounding stroma were analyzed in randomly selected specimens from 52 patients with prostate cancer and 28 patients with benign prostatic hyperplasia (BHP). To evaluate the intensity of tenascin-C, fibronectin and galectin-3 expression the percentage of positively immunostained stromal cells was examined.

Results: Compared to BPH, stroma of prostatic adenocarcinoma showed statistically significant increase in tenascin-C expression (p<0.001), predominantly around neoplastic glands, while fibronectin (p=0.001) and galectin-3 (p<0.001) expression in the same area was decreased.

Conclusions: Our study confirms changes in the expression of ECM proteins of prostate cancer which may have important role in the cancer development.

References

1. Mueller MM, Fusenig NE. Friends or foes [mdash] bipolar effects of the tumour stroma in cancer. Nat Rev Cancer. 2004;4(11):839-49.
http://dx.doi.org/10.1038/nrc1477


2. Tlsty TD, Coussens LM. TUMOR STROMA AND REGULATION OF CANCER DEVELOPMENT. Annual Review of Pathology: Mechanisms of Disease. 2006;1(1):119-50.
http://dx.doi.org/10.1146/annurev.pathol.1.110304.100224


3. Reticker-Flynn NE, Malta DFB, Winslow MM, Lamar JM, Xu MJ, Underhill GH, et al. A combinatorial extracellular matrix platform identifies cell-extracellular matrix interactions that correlate with metastasis. Nat Commun. 2012;3:1122.
http://dx.doi.org/10.1038/ncomms2128


4. Hägglöf C, Hammarsten P, Strömvall K, Egevad L, Josefsson A, Stattin P, et al. TMPRSS2-ERG Expression Predicts Prostate Cancer Survival and Associates with Stromal Biomarkers. PLoS ONE. 2014;9(2):e86824.
http://dx.doi.org/10.1371/journal.pone.0086824


5. Bosman FT, Stamenkovic I. Functional structure and composition of the extracellular matrix. The Journal of Pathology. 2003;200(4):423-8.
http://dx.doi.org/10.1002/path.1437


6. Tomas D, Kruslin B. The potential value of (Myo)fibroblastic stromal reaction in the diagnosis of prostatic adenocarcinoma. Prostate. 2004;61(4):324-31.
http://dx.doi.org/10.1002/pros.20109


7. Tomas D, Ulamec M, Hudolin T, Bulimbasic S, Belicza M, Kruslin B. Myofibroblastic stromal reaction and expression of tenascin-C and laminin in prostate adenocarcinoma. Prostate Cancer Prostatic Dis. 2006;9(4):414-9.
http://dx.doi.org/10.1038/sj.pcan.4500874


8. Tuxhorn JA, Ayala GE, Smith MJ, Smith VC, Dang TD, Rowley DR. Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clinical cancer research : an official journal of the American Association for Cancer Research. 2002;8(9):2912-23.

9. Hayward SW, Cunha GR, Dahiya R. Normal development and carcinogenesis of the prostate. A unifying hypothesis. Ann N Y Acad Sci. 1996;784(1):50-62.
http://dx.doi.org/10.1111/j.1749-6632.1996.tb16227.x


10. Shiraishi T, Kato H, Komada S, Imai H, Hirokawa Y, Kusano I, et al. Tenascin expression and postnatal development of the human prostate. The International journal of developmental biology. 1994;38(2):391-5.

11. Sakko AJ, Ricciardelli C, Mayne K, Suwiwat S, LeBaron RG, Marshall VR, et al. Modulation of prostate cancer cell attachment to matrix by versican. Cancer Res. 2003;63(16):4786-91.

12. Takenaka Y, Fukumori T, Raz A. Galectin-3 and metastasis. Glycoconj J. 2004;19(7-9):543-9.
http://dx.doi.org/10.1023/B:GLYC.0000014084.01324.15


13. Favaro WJ, Hetzl AC, Reis LO, Ferreira U, Billis A, Cagnon VH. Periacinar retraction clefting in nonneoplastic and neoplastic prostatic glands: artifact or molecular involvement. Pathology oncology research : POR. 2012;18(2):285-92.
http://dx.doi.org/10.1007/s12253-011-9440-5


14. Ao M, Brewer BM, Yang L, Franco Coronel OE, Hayward SW, Webb DJ, et al. Stretching fibroblasts remodels fibronectin and alters cancer cell migration. Sci Rep. 2015;5:8334.
http://dx.doi.org/10.1038/srep08334


15. Xue Y, Li J, Latijnhouwers MA, Smedts F, Umbas R, Aalders TW, et al. Expression of periglandular tenascin-C and basement membrane laminin in normal prostate, benign prostatic hyperplasia and prostate carcinoma. Br J Urol. 1998;81(6):844-51.
http://dx.doi.org/10.1046/j.1464-410x.1998.00659.x


16. Xue Y, Smedts F, Latijnhouwers MA, Ruijter ET, Aalders TW, de la Rosette JJ, et al. Tenascin-C expression in prostatic intraepithelial neoplasia (PIN): a marker of progression? Anticancer research. 1998;18(4A):2679-84.

17. Djakiew D. Dysregulated expression of growth factors and their receptors in the development of prostate cancer. The Prostate. 2000;42(2):150-60.
http://dx.doi.org/10.1002/(SICI)1097-0045(20000201)42:2<150::AID-PROS10>3.0.CO;2-H


18. Docheva D, Padula D, Schieker M, Clausen-Schaumann H. Effect of collagen I and fibronectin on the adhesion, elasticity and cytoskeletal organization of prostate cancer cells. Biochem Biophys Res Commun. 2010;402(2):361-6.
http://dx.doi.org/10.1016/j.bbrc.2010.10.034


19. Ioachim E, Charchanti A, Briasoulis E, Karavasilis V, Tsanou H, Arvanitis DL, et al. Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression. European Journal of Cancer. 2002;38(18):2362-70.
http://dx.doi.org/10.1016/S0959-8049(02)00210-1


20. van den Brûle FA, Waltregny D, Liu F-T, Castronovo V. Alteration of the cytoplasmic/nuclear expression pattern of galectin-3 correlates with prostate carcinoma progression. International Journal of Cancer. 2000;89(4):361-7.
http://dx.doi.org/10.1002/1097-0215(20000720)89:4<361::AID-IJC8>3.0.CO;2-U


21. Pacis RA, Pilat MJ, Pienta KJ, Wojno K, Raz A, Hogan V, et al. Decreased galectin-3 expression in prostate cancer. Prostate. 2000;44(2):118-23.
http://dx.doi.org/10.1002/1097-0045(20000701)44:2<118::AID-PROS4>3.0.CO;2-U


22. Fukumori T, Oka N, Takenaka Y, Nangia-Makker P, Elsamman E, Kasai T, et al. Galectin-3 Regulates Mitochondrial Stability and Antiapoptotic Function in Response to Anticancer Drug in Prostate Cancer. Cancer Research. 2006;66(6):3114-9.
http://dx.doi.org/10.1158/0008-5472.CAN-05-3750


23. Moisa A, Fritz P, Eck A, Wehner HD, Murdter T, Simon W, et al. Growth/adhesion-regulatory tissue lectin galectin-3: stromal presence but not cytoplasmic/nuclear expression in tumor cells as a negative prognostic factor in breast cancer. Anticancer research. 2007;27(4B):2131-9.
Published
2015-12-16
How to Cite
ULAMEC, Monika et al. Expression of extracellular matrix proteins: tenascin-C, fibronectin and galectin-3 in prostatic adenocarcinoma. Journal of Health Sciences, [S.l.], v. 5, n. 3, p. 72-77, dec. 2015. ISSN 1986-8049. Available at: <http://www.jhsci.ba/OJS/index.php/jhsci/article/view/314>. Date accessed: 25 sep. 2018. doi: https://doi.org/10.17532/jhsci.2016.314.
Section
Research articles

Keywords

ECM remodeling; fibronectin; galectin-3; tenascin-C; prostatic adenocarcinoma;